- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc stock price live, this page displays NASDAQ SLNO stock exchange data. View the SLNO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Soleno Therapeutics Inc real time stock price chart below.
What Is the Soleno Therapeutics Inc Stock Price Today?
The Soleno Therapeutics Inc stock price today is 68.0300.
What Is the Stock Symbol for Soleno Therapeutics Inc?
The stock symbol for Soleno Therapeutics Inc is ""SLNO.""
What Stock Exchange Does Soleno Therapeutics Inc Trade On?
Soleno Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Soleno Therapeutics Inc a Good Stock to Buy?
Determining whether Soleno Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLNO quote. (ISIN: US8342033094)
What Is the Soleno Therapeutics Inc Stock Price Today?
The Soleno Therapeutics Inc stock price today is 68.0300.
What Is the Stock Symbol for Soleno Therapeutics Inc?
The stock symbol for Soleno Therapeutics Inc is ""SLNO.""
What Stock Exchange Does Soleno Therapeutics Inc Trade On?
Soleno Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Soleno Therapeutics Inc a Good Stock to Buy?
Determining whether Soleno Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLNO quote. (ISIN: US8342033094)
NASDAQ
Currency in USD
68.0300
-0.3800(-0.56%)
Real-time Data·
Fair Value
An estimate of a Soleno Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
66.6142
68.9000
52 wk Range
41.5000
90.3199
SLNO Scorecard
Full Analysis
Net income is expected to grow this year
SLNO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Soleno Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
66.614268.9000
52 wk Range
41.500090.3199
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SLNO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Soleno Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
118.6000
Upside
+74.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price often moves in the opposite direction of the market
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Soleno Therapeutics Inc Company Profile
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Soleno Therapeutics Inc SWOT Analysis
FDA Milestone | Soleno Therapeutics secures FDA approval for VYKAT XR, a groundbreaking treatment for Prader-Willi Syndrome, positioning the company as a key player in rare disease therapeutics |
Market Dynamics | Explore the potential of VYKAT XR in a 10,000-patient market, with a strategic focus on 300 top specialists to drive initial adoption and maximize impact |
Financial Outlook | Delve into Soleno's robust financial position, with $285 million in cash reserves and a conservative revenue projection, as analysts set price targets ranging from $67 to $123 |
Competitive Edge | Uncover Soleno's advantages in the PWS treatment landscape, including unmet medical needs, strong clinical data, and a clean FDA label, potentially accelerating VYKAT XR's market penetration |
Soleno Therapeutics Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$0.09 beat forecast of -$0.64; revenue of $32.7M exceeded expectations by 113.03%
- VICAT XR launch successful; company exploring European market expansion for PWS treatment
- Pro forma cash balance over $500M; projecting annual cash operating expenses of $120-130M
- Stock dipped 0.54% post-earnings despite strong results; analyst targets suggest potential upside
- No new safety signals for VICAT XR; company actively seeking strategic partnerships for European entry
Last Updated: 07/08/2025, 08:36
Read Full TranscriptCompare SLNO to Peers and Sector
Metrics to compare | SLNO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLNOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.9x | −2.9x | −0.6x | |
PEG Ratio | 0.24 | 0.02 | 0.00 | |
Price/Book | 15.0x | 2.3x | 2.6x | |
Price / LTM Sales | 110.5x | 131.3x | 3.3x | |
Upside (Analyst Target) | 74.0% | 109.8% | 39.1% | |
Fair Value Upside | Unlock | 9.2% | 5.4% | Unlock |
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 118.6000
(+74.33% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
-0.09 / -0.64
Revenue / Forecast
32.70M / 15.35M
People Also Watch
FAQ
What Stock Exchange Does Soleno Therapeutics Trade On?
Soleno Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Soleno Therapeutics?
The stock symbol for Soleno Therapeutics is "SLNO."
What Is the Soleno Therapeutics Market Cap?
As of today, Soleno Therapeutics market cap is 3.62B.
What Is Soleno Therapeutics's Earnings Per Share (TTM)?
The Soleno Therapeutics EPS (TTM) is -3.97.
When Is the Next Soleno Therapeutics Earnings Date?
Soleno Therapeutics will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is SLNO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Soleno Therapeutics Stock Split?
Soleno Therapeutics has split 2 times.
How Many Employees Does Soleno Therapeutics Have?
Soleno Therapeutics has 133 employees.
What is the current trading status of Soleno Therapeutics (SLNO)?
As of 29 Aug 2025, Soleno Therapeutics (SLNO) is trading at a price of 68.0300, with a previous close of 68.41. The stock has fluctuated within a day range of 66.6142 to 68.9000, while its 52-week range spans from 41.5000 to 90.3199.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.